Exosome-based diagnostic developer Adipomics selected to join JLABS

Adipomics, a company that spun out of innovations discovered at Children’s National Health System, have been selected by Johnson & Johnson Innovation – JLABS to join  JPOD @ Boston,.

JLABS is a global network of no-strings-attached incubators for innovative companies from across the pharmaceutical, medical device, consumer and health technology sectors. Start-up companies are free to pursue their own research priorities independently, with access to state-of-the-art facilities to develop new drugs, medical devices, precision diagnostics and health technologies for people around the world.

Adipomics got their start at the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National. The Institute focuses on research and innovation that can improve health for children everywhere.

Adipomics was co-founded by pediatric surgeon Evan P. Nadler, M.D., co-director of the Obesity Program and director of the Bariatric Surgery Program at Children’s National, and Robert Freishtat, M.D., M.P.H., senior investigator in the Center for Genetic Medicine of the Children’s Research Institute and chief of the Division of Emergency Medicine at Children’s National. Adipomics was founded with the aim to address the global epidemic of obesity-related diseases including Type 2 diabetes and cardiovascular diseases. World health experts predict that one billion people worldwide will be obese by 2030.

Drs. Nadler and Freishtat discovered that exosomes released from fat cells (adipocytes) carry genetic material that can mediate various diseases related to obesity. Through their research, they developed a proprietary method that aims to detect how obesity affects an individual patient’s metabolism before the onset of overt disease. Adipomics aims to create the first non-invasive, “anticipatory medicine” diagnostic that detects risk for obesity-related diseases prior to the onset of clinical signs or even biochemical abnormalities. If successful, this predictive methodology would enable treatment much earlier in the disease process, which is likely to improve effectiveness.

The company’s current focus is developing a diagnostic product for the anticipatory detection of Type 2 diabetes and cardiovascular diseases, based on blood and urine tests that measure changes in fat cell-derived exosomal microRNAs that lead to activation of relevant disease pathways. Adipomics is also developing a gene therapy platform for treating single-gene defect diseases using genetically engineered, fat cell-derived exosomes.

Founded in 2015, Adipomics has participated in grants totaling over $1.5 million and will open its first international laboratory in India in 2020.

Source – Children’s National Health System

Leave a Reply

Your email address will not be published. Required fields are marked *

*